In this context, dual-specific inhibitors of APN/DPP4 have been developed and have been proven to be effective in vitro and in vivo, e.g., in mouse models of multiple sclerosis or stroke [48,50,161]. This evidence concerns the gene ANPEP and stroke disorder.